Krilogy Financial’s Esperion Therapeutics ESPR Stock Holding History

Krilogy Financial’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-11,472	Closed	-$36.3K	–	1116
2026 Q2	$36.3K	Buy	+11,472	New	+$32.1K	﹤0.01%	1046
2017 Q4	–	Sell	-200	Closed	-$10K	–	786
2017 Q3	$10K	Hold	200	–	–	﹤0.01%	576
2017 Q2	$9K	Hold	200	–	–	﹤0.01%	542
2017 Q1	$3K	Hold	200	–	–	﹤0.01%	618
2016 Q4	$3K	Hold	200	–	–	﹤0.01%	618
2016 Q3	$3K	Hold	200	–	–	﹤0.01%	634
2016 Q2	$2K	Hold	200	–	–	﹤0.01%	678
2016 Q1	$3K	Hold	200	–	–	﹤0.01%	576
2015 Q4	$4K	Hold	200	–	–	﹤0.01%	330
2015 Q3	$5K	Buy	+200	New	+$12.6K	﹤0.01%	463

Krilogy Financial's ESPR Position: Q3 2026 in Review

Krilogy Financial sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 11,472 shares — an estimated $36.3K sold.

Krilogy Financial first reported a position in ESPR in Q3 2015 and held it in 10 quarters. The position peaked at $36.3K in Q2 2026. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

Krilogy Financial reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
Krilogy Financial sold 11,472 Esperion Therapeutics shares in Q3 2026, an estimated $36.3K.
Krilogy Financial first reported a position in Esperion Therapeutics in Q3 2015 and held it in 10 quarters.
Krilogy Financial's Esperion Therapeutics position peaked at $36.3K in Q2 2026.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Krilogy Financial's 13F filing for Q3 2026, filed 13 Oct 2026.